Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2025)

Catalyst Pharmaceuticals' FCF Margin history spans 11 years, with the latest figure at 29.39% for Q4 2025.

  • For Q4 2025, FCF Margin fell 2052.0% year-over-year to 29.39%; the TTM value through Dec 2025 reached 35.42%, down 1324.0%, while the annual FY2025 figure was 35.42%, 1324.0% down from the prior year.
  • FCF Margin reached 29.39% in Q4 2025 per CPRX's latest filing, up from 21.86% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 72.15% in Q3 2022 to a low of 9.61% in Q1 2021.
  • Average FCF Margin over 5 years is 42.11%, with a median of 46.26% recorded in 2025.
  • Peak YoY movement for FCF Margin: skyrocketed 2137bps in 2024, then crashed -3456bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 49.95% in 2021, then surged by 32bps to 65.96% in 2022, then decreased by -24bps to 50.25% in 2023, then dropped by -1bps to 49.91% in 2024, then crashed by -41bps to 29.39% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's FCF Margin are 29.39% (Q4 2025), 21.86% (Q3 2025), and 48.63% (Q2 2025).